Sensei launches diabetes iPhone app

Share this article:
Sensei launches diabetes iPhone app
Sensei launches diabetes iPhone app

Sensei, a mobile technology developer and subsidiary of Humana, has launched an iPhone application for patients with diabetes.

 

The diabetes “app,” in Apple parlance, is called My Diabetes Guide, and helps diabetics manage their condition by offering instructions on “what to do, what to know, what to eat and what to ask their doctors,” according to a company statement. Speaking on the need for a mobile diabetes management tool, Robert Schwarzberg, president and CEO, Sensei, said: "Programs online have extensive and valuable content with less a focus and access to the seamless activity we hope to participate in. Lifestyle change isn't what happens while sitting in front of your PC." Patients can download the app for 99 cents through Apple's iTunes app store. 
 

To help facilitate the patient/physician relationship, My Diabetes Guide offers checklists of items to bring and questions to ask, as well as what to expect at a check-up. Regarding potential partnerships with pharma, Schwarzberg said the company is "in discussions to customize the program for other stakeholders addressing their needs and interests including availability on most handsets.  These new tools of engagement we believe will enhance compliance and brand loyalty." Schwarzberg was not at liberty to comment on any current partnerships with pharmaceutical or medical device marketers.

Lifescan, a subsidiary of Johnson & Johnson, recently debuted a prototype application for the iPhone that would synch glucose meter readings with the iPhone, allowing diabetes patients to manage their blood sugar on the device.

Share this article:

Email Newsletters

More in News

Gilead reaps huge HCV sales, payer fury

Gilead reaps huge HCV sales, payer fury

Sovaldi's debut has been marked by plenty of criticism from payers and lawmakers, but the hep. C drug's launch, now confirmed to be the fastest of all time, has also ...

Bayer drug gets orphan label

Bayer drug gets orphan label

The FDA designation is for an experimental, inhaled form of ciprofloxacin intended to treat a rare lung condition.

Lilly's cancer drug ramu granted gastric indication

Lilly's cancer drug ramu granted gastric indication

Ramucirumab received FDA approval today in advanced gastric cancer, a nod that could translate into $600 million in peak sales.